Imatinib Aspire

Imatinib, the active ingredient in Imatinib Aspire, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Aspire as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib Aspire targets BCR‑ABL driven malignancies and related tyrosine‑kinase pathways.

Chronic Myeloid Leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and delays disease progression. Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted inhibition of leukemic blasts.

Imatinib Aspire may cause a range of adverse reactions.

Common Side Effects: - Nausea or vomiting - Fluid retention or peripheral edema - Muscle cramps or weakness - Fatigue or tiredness - Diarrhea or abdominal discomfort - Skin rash or pruritus

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity with elevated liver enzymes - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Tumor lysis syndrome in high‑burden disease

Before initiating therapy, clinicians should assess baseline parameters and monitor patients regularly.

Monitor blood counts: perform complete blood count at baseline and periodically. Assess liver function: check hepatic enzymes before and during treatment. Evaluate cardiac status: perform echocardiogram if there is a history of heart disease. Avoid in patients with known hypersensitivity to imatinib or its excipients. Use caution in severe renal or hepatic impairment: dose adjustment may be required. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib can interact with several concomitant medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib plasma levels. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic exposure. - Concomitant use with antacids containing aluminum or magnesium: can decrease absorption.

Moderate Interactions (Monitor Closely): - Warfarin: imatinib may enhance anticoagulant effect; monitor INR. - Diuretics (e.g., furosemide): increased risk of fluid retention. - QT‑prolonging agents (e.g., sotalol): monitor cardiac rhythm and electrolytes.